Childhood onset of migraine, gender, psychological distress and locus of control as predictors of migraine in adulthood

Furnham, Adrian; Cheng, Helen

doi:10.1080/13548506.2022.2129083

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 Moreover, early-onset migraine, particularly before age 12 years, is a potent predictor of chronic migraine in adulthood, highlighting the crucial need for effective interventions during this critical developmental window. 14,15 The highest growth in migraine incidence among children, adolescents, and young adults in the last 30 years (1990−2019) occurred in individuals aged 10−14 years. 2 However, the landscape for the acute treatment of migraine in children aged 6−12 years is extremely limited.…”

Section: Introductionmentioning

confidence: 99%

“…In general, headache disorders constitute the second predominant contributor to disability‐adjusted life‐years in adolescents and young adults aged 10−24 years, according to the Global Burden of Disease Study 2019 12,13 . Moreover, early‐onset migraine, particularly before age 12 years, is a potent predictor of chronic migraine in adulthood, highlighting the crucial need for effective interventions during this critical developmental window 14,15 . The highest growth in migraine incidence among children, adolescents, and young adults in the last 30 years (1990−2019) occurred in individuals aged 10−14 years 2…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute treatment of migraine in children aged 6−11: Real‐world analysis of remote electrical neuromodulation (REN)

Werner,

Gerson,

Stark‐Inbar

et al. 2024

Annals of the Child Neurology Society

View full text Add to dashboard Cite

ObjectivesMigraine is a prevalent neurological disorder severely impacting children and adolescents, yet only one pharmacological treatment is approved for ages 6−12 years. Remote electrical neuromodulation (REN) is a nonpharmacological, prescribed, wearable device cleared by the Food and Drug Administration for acute and/or preventive treatment of migraine with or without aura in patients 12 years and older. This study evaluates REN's safety and efficacy in ages 6−11 years.MethodsProspective acute treatment of migraine data were collected through the REN device (Nerivio) smartphone application. Endpoints were device safety (primary); consistent treatment efficacy (headache pain, functional disability, associated migraine symptoms), and REN‐medication combinations 2 h post‐treatment.ResultsChildren (n = 293), median age 11 years (interquartile range = 9−11), 73.7% girls, conducted 5493 REN treatments. No adverse events were reported. Efficacy in at least 50% of REN treatments was calculated from all patients who voluntarily reported pain levels, symptoms, and/or disability at treatment onset and at 2 h post‐treatment, with 72.2% (13/18) of patients reporting pain relief, 36.0% (9/25) pain freedom, 83.3% (15/18) functional disability relief, and 38.9% (7/18) functional disability freedom. Migraine‐associated symptoms disappeared in at least 50% of REN treatments in 70.0% (7/10) of patients for nausea/vomiting, 50.0% (4/8) phonophobia, and 22.2% (2/9) photophobia; 63.6% (7/11) reported freedom from at least one associated symptom. REN was used as a standalone treatment, with over‐the‐counter medications, and with prescribed headache medications in 45.4%, 34.4%, and 20.9% of treatments, respectively.InterpretationREN may serve as a safe and efficacious acute treatment of migraine for children. Providers and families seeking a safe, effective, pill‐ and needle‐free treatment option for children suffering from migraine may consider REN.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%